Taiwan's first COVID-19 vaccine approved for clinical trial

The Food and Drug Administration (FDA) in Taiwan announced the conditional approval of a COVID-19 vaccine developed by Adimmune Corporation to enter Phase I clinical trials, which is the first company in Taiwan to conduct human tests. It will expect to receive more than 60 healthy volunteers for the trial.

Taiwan recently held a meeting of experts to review the Phase I clinical trial of a vaccine candidate, AdimrSC-2f vaccine, from Adimmune Corporation.

The meeting decided to grant conditional approval of Adimmune Corporation conducting a Phase I clinical trial, subject to further evaluation of the vaccine's efficacy.